Results 31 to 40 of about 1,064,547 (319)

Genomic Diversity and Clinical Variability in Pediatric Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Series

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a rare pediatric CD30‐positive T‐cell lymphoproliferative disorder with an excellent prognosis, but its genomic drivers are poorly defined. We report three children with skin‐limited disease demonstrating striking molecular heterogeneity, including NPM::ALK, NUP214::FRK, and a novel ...
Shoshana Greenberger   +7 more
wiley   +1 more source

Therapeutics Letter 121 [PDF]

open access: yes, 2019
Therapeutics Letter 121 is the first of two issues celebrating 25 years of The Therapeutics Initiative by highlighting key conclusions from the 120 issues of the Therapeutics Letter that have been published to date.Medicine, Faculty ofAnesthesiology ...
Therapeutics Initiative (University of British Columbia)
core  

Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses

open access: yesNature Communications
Mucopolysaccharidoses are inherited metabolic disorders caused by the deficiency in lysosomal enzymes required to break down glycosaminoglycans. Accumulation of glycosaminoglycans leads to progressive, systemic degenerative disease.
Panagiotis Douvaras   +26 more
doaj   +1 more source

A Comprehensive Overview of circRNAs: Emerging Biomarkers and Potential Therapeutics in Gynecological Cancers

open access: yesFrontiers in Cell and Developmental Biology, 2021
Circular RNA (circRNA) is a highly conserved, stable and abundant non-coding RNA (ncRNA). Also, some circRNAs play an essential part in the progression of human cancers. CircRNA is different from traditional linear RNA.
Yalan Ma   +5 more
doaj   +1 more source

Therapeutics Letter 64 [PDF]

open access: yes, 2007
Therapeutics Letter 64 provides results of the Therapeutics Initiative's (TI) third readership survey to evaluate perceptions of TI educational activities.Medicine, Faculty ofAnesthesiology, Pharmacology and Therapeutics, Department ofReviewedThe UBC TI ...
Therapeutics Initiative (University of British Columbia)
core  

AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models

open access: yesNature Communications
Hypertrophic cardiomyopathy (HCM) affects approximately 600,000 people in the United States. Loss-of-function mutations in Myosin Binding Protein C3, MYBPC3, are the most common genetic cause of HCM, with the majority of mutations resulting in ...
Amara Greer-Short   +29 more
doaj   +1 more source

Retinoblastoma: A review of the molecular basis of tumor development and its clinical correlation in shaping future targeted treatment strategies

open access: yesIndian Journal of Ophthalmology, 2023
Retinoblastoma is a retinal cancer that affects children and is the most prevalent intraocular tumor worldwide. Despite tremendous breakthroughs in our understanding of the fundamental mechanisms that regulate progression of retinoblastoma, the ...
Shruti Rathore   +8 more
doaj   +1 more source

Are Fertility Preservation Procedures Before Gonadotoxic Therapy and Hematopoietic Stem Cell Transplantation Feasible and Safe in Very Young Children? A Retrospective Cohort Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Fertility preservation (FP) is increasingly integrated into the care of pediatric patients exposed to gonadotoxic therapy or conditioning for hematopoietic stem cell transplantation (HSCT), yet perioperative data in infants and toddlers remain scarce.
Kerstin Saalabian   +13 more
wiley   +1 more source

Therapeutics Letter 86 [PDF]

open access: yes, 2012
Therapeutics Letter 86 provides results of the Therapeutics Initiative's (TI) fourth readership survey to evaluate perceptions of TI educational activities.Medicine, Faculty ofAnesthesiology, Pharmacology and Therapeutics, Department ofReviewedThe UBC TI
Therapeutics Initiative (University of British Columbia)
core  

Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice

open access: yesNature Communications
Heart failure with preserved ejection fraction (HFpEF) poses therapeutic challenges due to the limited treatment options. Building upon our previous research that demonstrates the efficacy of histone deacetylase 6 (HDAC6) inhibition in a genetic ...
Sara Ranjbarvaziri   +18 more
doaj   +1 more source

Home - About - Disclaimer - Privacy